Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
227 search results for:

Umeclidinium 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Umeclidinium | Erratum

    Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

    HCRU and costs following FF/UMEC/VI initiation.

    Author:
    Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
    Published in:
    Respiratory Research > Issue: 1 / 2024
  2. 01-09-2023 | Umeclidinium | News

    Umeclidinium
    Lack of efficacy: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2023
  3. Open Access 01-12-2023 | Umeclidinium | OriginalPaper

    Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

    Escalation to triple therapy with an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) who continue to …

    Author:
    Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
    Published in:
    Respiratory Research > Issue: 1 / 2023
  4. Open Access 01-12-2021 | Umeclidinium | OriginalPaper

    Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

    In patients with chronic obstructive pulmonary disease (COPD), exacerbations are associated with increased disease burden and higher healthcare costs [ 1 ]. As such, reducing the risk of exacerbations is an important goal of maintenance therapy in …

    Author:
    David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran, Beth Hahn
    Published in:
    BMC Pulmonary Medicine > Issue: 1 / 2021
  5. Open Access 01-06-2021 | Umeclidinium | OriginalPaper

    Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease

    This article is published with digital features, including a summary slide and plain language summary, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13953734 .

    Author:
    David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D. MacKnight, Beth Hahn
    Published in:
    Pulmonary Therapy > Issue: 1 / 2021
  6. 01-07-2021 | Umeclidinium | OriginalPaper

    Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)

    Despite adherence to inhaled corticosteroids/long-acting β 2 -agonist (ICS/LABA) maintenance therapy, approximately 30–50% of patients with asthma are still not well controlled [ 1 – 4 ]. Guidelines from the Global Initiative for Asthma [ 5 ] …

    Author:
    Shuying Yang, Laurie A. Lee, Neal Sule, Andrew Fowler, Guy Peachey
    Published in:
    Clinical Pharmacokinetics > Issue: 7 / 2021
  7. Open Access 02-09-2022 | Umeclidinium | Erratum

    Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

    The authors regret to inform readers that the labels for the ‘treatment favour’ arrows were incorrectly labelled in Fig. 4. The ‘Favours UMEC/VI 62.5/25’ and ‘Favours comparator’ labels were appended to the wrong arrows and the corrected Fig. 4 is …

    Author:
    Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier, David M. G. Halpin
    Published in:
    Advances in Therapy > Issue: 11 / 2022
  8. Open Access 20-07-2022 | Umeclidinium | OriginalPaper

    Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

    Long-acting bronchodilators are the mainstay of maintenance therapy for patients with chronic obstructive pulmonary disease (COPD). However, treatment guidelines provide different recommendations on when to initiate long-acting muscarinic …

    Author:
    Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier, David M. G. Halpin
    Published in:
    Advances in Therapy > Issue: 11 / 2022
  9. Open Access 01-12-2020 | Umeclidinium | OriginalPaper

    A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

    Asthma, a common chronic condition, can occur at all ages [ 1 – 3 ]. In 2015, the prevalence of asthma was 358.2 million worldwide, reflecting an increase of 12.6% from 1990 [ 1 ]. Asthma is associated with respiratory symptoms and variable airflow …

    Author:
    Edward Kerwin, Steven Pascoe, Zelie Bailes, Robert Nathan, David Bernstein, Ronald Dahl, Robyn von Maltzahn, Kevin Robbins, Andrew Fowler, Laurie Lee
    Published in:
    Respiratory Research > Issue: 1 / 2020
  10. Open Access 01-12-2020 | Umeclidinium | OriginalPaper

    Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

    Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by chronic airflow limitation and persistent respiratory symptoms [ 1 ]. COPD is associated with a substantial clinical burden [ 1 ], was the third leading …

    Author:
    Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson
    Published in:
    Respiratory Research > Issue: 1 / 2020
  11. Open Access 01-12-2021 | Umeclidinium | OriginalPaper

    Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

    In chronic obstructive pulmonary disease (COPD) a widely accepted definition of reversibility is a ≥ 12% and ≥ 200 mL improvement from pre-bronchodilator baseline in forced expiratory volume in 1 s (FEV 1 ) within 60 min of inhalation of a single …

    Author:
    Claus F. Vogelmeier, Paul W. Jones, Edward M. Kerwin, Isabelle H. Boucot, François Maltais, Lee Tombs, Chris Compton, David A. Lipson, Leif H. Bjermer
    Published in:
    Respiratory Research > Issue: 1 / 2021
  12. Open Access 01-09-2021 | Umeclidinium | OriginalPaper

    Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial

    In patients with chronic obstructive pulmonary disease (COPD), poorly controlled symptoms are associated with worse health-related quality of life, increased risk of COPD exacerbations, and a poor disease prognosis [ 1 – 3 ]. Smoking is one of the …

    Author:
    Leif H. Bjermer, Isabelle H. Boucot, Claus F. Vogelmeier, François Maltais, Paul W. Jones, Lee Tombs, Chris Compton, David A. Lipson, Edward M. Kerwin
    Published in:
    Advances in Therapy > Issue: 9 / 2021
  13. 01-09-2019 | Umeclidinium | OriginalPaper

    A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD

    The pharmacological treatment of chronic obstructive pulmonary disease (COPD) typically includes single or dual long-acting bronchodilators, with the primary goals of reducing symptoms and the risk of COPD exacerbations [ 1 ]. Dual combinations of …

    Author:
    François Maltais, Gary T. Ferguson, Gregory J. Feldman, Gaëtan Deslee, Arnaud Bourdin, Harald Fjällbrant, Agnieszka Siwek-Posłuszna, Martin A. Jenkins, Ubaldo J. Martin
    Published in:
    Advances in Therapy > Issue: 9 / 2019
  14. Open Access 04-02-2024 | Chronic Obstructive Lung Disease | OriginalPaper

    Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

    Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition estimated to affect 4.6–6.6% of American adults [ 1 ], and is a leading cause of death worldwide [ 2 ]. The economic and social burden of COPD is considerable, with …

    Author:
    Meredith McCormack, Rosirene Paczkowski, Noelle N. Gronroos, Stephen G. Noorduyn, Lydia Lee, Phani Veeranki, Mary G. Johnson, Emmeline Igboekwe, Kristin Kahle-Wrobleski, Reynold Panettieri
    Published in:
    Advances in Therapy > Issue: 3 / 2024
  15. Open Access 01-12-2019 | Umeclidinium | OriginalPaper

    Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

    Long-acting bronchodilators, including long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists (LABAs), form the basis of maintenance therapy in chronic obstructive pulmonary disease (COPD) [ 1 ]. The recommended first-line …

    Author:
    François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus F. Vogelmeier
    Published in:
    Respiratory Research > Issue: 1 / 2019
  16. Open Access 01-12-2018 | OriginalPaper

    Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

    Inhaled long-acting bronchodilators form the foundation of chronic obstructive pulmonary disease (COPD) therapy, with treatment strategies including long-acting muscarinic antagonist (LAMA) or long-acting β 2 -agonist (LABA) monotherapy, or a …

    Author:
    Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa, Gregory Feldman
    Published in:
    Pulmonary Therapy > Issue: 2 / 2018
  17. 01-11-2016 | ReviewPaper

    Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials

    Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing [ 1 – 3 ]. Current treatment guidelines for COPD recommend …

    Author:
    Li Wang, Chun-juan Zhai, Yao Liu, Yi Liu, Shu-juan Jiang
    Published in:
    Clinical Drug Investigation > Issue: 11 / 2016
  18. 01-02-2017 | OriginalPaper

    Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma

    Many patients with asthma remain symptomatic despite the use of current treatments, therefore, alternative therapies are needed [ 1 , 2 ]. Inhaled long-acting muscarinic antagonists (LAMAs) are well established as a treatment option for patients …

    Author:
    Shuying Yang, Laurie Lee, Steven Pascoe
    Published in:
    European Journal of Drug Metabolism and Pharmacokinetics > Issue: 1 / 2017
  19. 01-03-2016 | ReviewPaper

    Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis

    A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be …

    Author:
    Roy A. Pleasants, Tiansheng Wang, Jinming Gao, Huilin Tang, James F. Donohue
    Published in:
    Drugs > Issue: 3 / 2016
  20. 01-07-2016 | OriginalPaper

    Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU

    Umeclidinium/vilanterol (Anoro®; Laventair™) delivered via a dry-powder inhaler (Ellipta™) is a fixed-dose combination of a long-acting muscarinic receptor antagonist (umeclidinium) and a long-acting β2-adrenoceptor agonist (vilanterol).

    Author:
    Yahiya Y. Syed, Katherine A. Lyseng-Williamson, Hannah A. Blair, Emma D. Deeks
    Published in:
    Drugs & Therapy Perspectives > Issue: 7 / 2016

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.